Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966276 | 0.90 | KDM4E (0.41) | HCRTR1HCRTR2DRD3TRPV1KDM4E | |
| SCHEMBL5962886 | 0.86 | SPHK2 (0.46) | SPHK2HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL5962885 | 0.86 | SPHK2 (0.45) | SPHK2HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL5962759 | 0.85 | ROCK2 (0.39) | HCRTR1HCRTR2DRD2TRPV1MEN1 | |
| SCHEMBL5963019 | 0.84 | SPHK2 (0.45) | SPHK2HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL5962819 | 0.80 | SPHK2 (0.54) | SPHK2HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL5962794 | 0.78 | SPHK2 (0.51) | SPHK2HCRTR1HCRTR2DRD2DRD3 | |
| SCHEMBL5966275 | 0.75 | KDM4E (0.41) | HCRTR1HCRTR2DRD3TRPV1KDM4E | |
| SCHEMBL5966272 | 0.74 | KDM4E (0.40) | HCRTR1HCRTR2DRD2DRD3TRPV1 | |
| SCHEMBL13594856 | 0.74 | KMT2A (0.51) | SPHK2HCRTR1HCRTR2TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067511-B2 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2006-06-27 | — | — | US | disclosed |
| US-7049311-B1 | Pyrrolbenzodiazepines | SPIROGEN LIMITED (GB) | 2006-05-23 | — | — | US | disclosed |
| EP-1109812-B1 | PYRROLOBENZODIAZEPINES | SPIROGEN LTD (GB) | 2005-05-04 | — | — | EP | disclosed |
| EP-1413582-A1 | Dimeric pyrrolobenzodiazepines | Spirogen Limited (GB) | 2004-04-28 | — | — | EP | disclosed |
| US-20030120069-A1 | Pyrrolobenzodiazepines | SPIROGEN LIMITED (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1193270-A2 | Pyrrolobenzodiazepines | Spirogen Limited (GB) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120069-A1 | Pyrrolobenzodiazepines | CNR1, CBX2, CNR2 | SPHK2 4542/4885HCRTR1 76/4885HCRTR2 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.